ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Viking Therapeutics (VKTX) pipeline and stated timing

Name in SEC filings: Viking Therapeutics, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
VK2735/data readoutPhase 225EX-99.1 ·
VK2735Topline/data readoutStage not stated26EX-99.1 ·

Source: ORION, orionbiotechai.com/company/VKTX, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/VKTX

Latest retained statement: VK2735 · Topline/data readout · 3Q26 · EX-99.1 filed

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
VK2735Clinical results3Q26
“Maintenance Dosing Study Data Expected 3Q26”

Filed · EX-99.1

Disclosure present

SEC filing date within the stated period

Filed · EX-99.1

“top-line results from the company’s maintenance study of VK2735”
VK2735Clinical results3Q26
“Maintenance Dosing Study Advances; Data Expected 3Q26”

Filed · EX-99.1

Disclosure present

SEC filing date within the stated period

Filed · EX-99.1

“top-line results from the company’s maintenance study of VK2735”
VK2735Clinical results3Q26
“Phase 1 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26”

Filed · EX-99.1

Disclosure present

SEC filing date within the stated period

Filed · EX-99.1

“top-line results from the company’s maintenance study of VK2735”
VK2735Clinical results2H25
“Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected in 2H25”

Filed · EX-99.1

Disclosure present

SEC filing date within the stated period

Filed · EX-99.1

“top-line results from the company’s Phase 2 clinical trial of the oral tablet formulation of VK2735”

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained founder-checked records

These dated records retain their original scope and check dates.

VK2735 · Maintenance Dosing Data

Record VKTX-03 · Clinical results disclosure · Disclosure found

Last checked: .

First stated window
“3Q26”SEC Form , Exhibit 99.1, filed
Disclosure date
SEC Form 8-K, Exhibit 99.1 · SEC original

Initial statement

· Checked by founder · SEC Form 8-K, Exhibit 99.1

Stated period: 3Q26

In January 2026, Viking announced completion of enrollment in the maintenance dosing study. The company expects to report the results of the study in 3Q26.

Reaffirmation

· Checked by founder · SEC Form 8-K, Exhibit 99.1

Stated period: 3Q26

In January 2026, Viking announced completion of enrollment in the maintenance dosing study. The company expects to report the results of the study in 3Q26.

Reaffirmation

· Checked by founder · SEC Form 8-K, Exhibit 99.1

Stated period: 3Q26

VK2735 Maintenance Dosing Data Expected 3Q26

Disclosure found

· Checked by founder · SEC Form 8-K, Exhibit 99.1

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company’s maintenance study of VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Additional disclosure

· Checked by founder · SEC Form 8-K (Cover filing)

Stated period: September 22, 2026

On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Sources and scope

Scope source

· SEC 8-K, Exhibit 99.1

monthly subcutaneous dosing, daily oral dosing, and weekly oral dosing

Scope source

· SEC 8-K, Exhibit 99.1

The company plans to explore oral maintenance dosing regimens in an upcoming part 2 to the current study.

Scope source

· Company press release

We look forward to reporting the results from Part 2 of this study in 2027.

Scope source

· SEC Form 10-Q

Company release: · Company original

Sept 22 reported results from the subcutaneous arms; oral maintenance was described as an upcoming Part 2. On Oct 6 the company started Part 2 (oral and additional subcutaneous regimens) and expects results in 2027. ORION has not yet published a separate record for Part 2.

The Form filed 2026-04-30 contains a maintenance study description; no results timing window was located. Omission in this quarterly document does not establish cancellation.

SEC filings searched through : 2/11, 4/29, 7/29, 9/22 8-K Exhibit 99.1 and 4/30 10-Q checked for maintenance study results timing.

Company press releases checked : Viking IR releases of 7/29, 9/22, 10/6 checked. Not all company channels.

Checked by founder: .

Corrections

Viking Therapeutics (VKTX) — VK2735 · Maintenance Dosing Data: “3Q26” (SEC Form 8-K, Exhibit 99.1 2026-02-11); statement retained “3Q26” (2026-04-29); statement retained “3Q26” (2026-07-29); disclosure 2026-09-22. Status Disclosure found, checked 2026-10-08. Sources: https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm | https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm

Retained program pages

Retained company announcements

Historical summaries and source dates are retained separately from the SEC timing quotes above. Earlier publications were collected retrospectively.

Historical catalog checked .

No historical announcement trail is retained for this company in this catalog.

Retained Weekly announcement note · Source published · Original company release

This announcement note is not part of the retained guidance trail or asserted to be the same trial as the selected registry study.

Selected registry record

VK2735 subcutaneous · NCT07104383

Condition in the selected registry record
Weight Loss
Phase in the selected registry record
Phase 3
Identity checked
Phase metadata checked

Original ClinicalTrials.gov record · Open the selected study

Retained company–study identity sources

Scope of retained company and registry evidence

These are selected linked records and dated source metadata, not a live registry recheck or the company’s full pipeline. Company announcements and the selected registry study are separate evidence sets. No stage or event timing is borrowed between them.

Coverage and identity checks

Watch VKTX

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for VKTX. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See VKTX in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.1H means January–June and 2H means July–December of the stated year, unless the company uses a different fiscal year.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.